FDA expands Bravecto Quantum label for two more dog tick species

Merck Animal Health said the FDA has approved an expanded label for Bravecto Quantum, adding 12-month treatment and control claims in dogs for the Asian longhorned tick (Haemaphysalis longicornis) and the Gulf Coast tick (Amblyomma maculatum). The product, a veterinarian-administered extended-release fluralaner injection, was first approved on July 10, 2025, as the first FDA-approved flea and tick treatment for dogs with 8- to 12-month duration, depending on tick species. With this update, Bravecto Quantum now carries 12-month claims for Asian longhorned, Gulf Coast, black-legged, American dog, and brown dog ticks, while lone star tick protection remains limited to 8 months. (merck-animal-health-usa.com)

Why it matters: For veterinarians, the label expansion broadens the species coverage on a long-acting injectable that already stands out for duration and clinic-controlled administration. That could matter most in regions seeing spread of the invasive Asian longhorned tick, which USDA APHIS tracks in established populations across multiple U.S. counties, and in areas where Gulf Coast tick exposure is relevant. It also gives practices another talking point around adherence, though clinicians still need to match dosing intervals to local tick risk because dogs exposed to lone star ticks may need re-dosing at 8 months, not 12. FDA also continues to note the isoxazoline class warning for potential neurologic adverse reactions, including tremors, ataxia, and seizures in some dogs and cats. (aphis.usda.gov)

What to watch: Watch for how quickly Merck updates field messaging and practice materials after a recent National Advertising Division challenge over year-round tick-protection claims tied to lone star tick exposure. (bbbprograms.org)